Senores Pharmaceuticals Limited

NSEI:SENORES Stock Report

Market Cap: ₹24.5b

Senores Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NSEI:SENORES Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
27 Jan 25Buy₹2,017,760Renosen Pharmaceuticals Private LimitedCompany4,000₹504.44

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of SENORES?
Owner TypeNumber of SharesOwnership Percentage
Public Companies3,261,7447.08%
Institutions3,594,9187.81%
Private Companies6,611,25414.4%
General Public15,774,21034.3%
Individual Insiders16,811,46236.5%

Dilution of Shares: SENORES only recently listed within the past 12 months


Top Shareholders

Top 25 shareholders own 65.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.15%
Ashokkumar Barot
4,214,605₹2.2b0%no data
7.98%
Swapnil Shah
3,676,031₹2.0b0%no data
7.08%
Remus Pharmaceuticals Limited
3,261,744₹1.7b0%no data
5.86%
Renosen Pharmaceuticals Private Limited
2,698,219₹1.4b0.15%no data
4.98%
Anar Shah
2,294,500₹1.2b0%no data
4.12%
Aviraj Overseas LLC
1,895,190₹1.0b0%no data
2.81%
Aditya Birla Sun Life Insurance Company Limited, Asset Management Arm
1,295,538₹689.3m0%no data
2.78%
ICICI Prudential Asset Management Company Limited
1,278,738₹680.4m-5.53%0.01%
2.26%
Sangita Barot
1,042,955₹554.9m0%no data
1.88%
Manoj Sanghvi
866,984₹461.3m0%no data
1.82%
Ratnamani Marketing Pvt Ltd
838,095₹445.9m0%no data
1.77%
Jitendra Sanghvi
817,085₹434.7m0%no data
1.49%
Aviraj Group LLC
684,750₹364.3m0%no data
1.45%
Jayantilal Sanghvi
666,663₹354.7m0%no data
1.19%
Jigar Sanghvi
549,523₹292.4m0%no data
1.11%
BOI Star Investment Managers Private Limited
511,480₹272.1m0%0.34%
1.11%
Mahindra Manulife Investment Management Pvt. Ltd.
509,162₹270.9m0%0.11%
1.1%
Pavankumar Sanghvi
507,936₹270.2m0%no data
1.07%
Espee Therapeutics LLP
495,000₹263.4m0%no data
1.03%
Prakash Sanghvi
476,190₹253.4m0%no data
0.99%
Sheetal Sanghvi
454,288₹241.7m0%no data
0.88%
Ravi Sanghvi
406,402₹216.2m13,500,000%no data
0.72%
Shantilal Sanghvi
333,331₹177.3m11,100,000%no data
0.58%
Dimple Sanghvi
266,842₹142.0m0%no data
0.52%
Rashmidevi Sanghvi
238,095₹126.7m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/05 14:06
End of Day Share Price 2025/02/05 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Senores Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.